Lutris Pharma a yau ya sanar da cewa ya kammala rajista na kashi na biyu na gwajin gwaji na asibiti na kashi 1/2 na sinadarin gubar, LUT014, wanda aka yi amfani da shi, novel B-Raf inhibitor, don maganin dermatitis da ke haifar da radiation (RD) a cikin marasa lafiya tare da ciwon nono. Ana sa ran bayanan manyan layi a cikin kwata na uku na 2022.
Bazuwar, makafi biyu, kashi biyu mai sarrafa wuribo na kashi na 1/2 na binciken ya shiga jimillar marasa lafiya 20 kuma an tsara shi don kimanta ingancin kulawar LUT014 a cikin marasa lafiya na nono tare da RD. An ba da izini ga marasa lafiya a cikin rabo na 1: 1 don karɓar ko dai ana gudanar da LUT014 ko placebo na kwanaki 28, sannan bayan watanni 2 na biyo baya.
Babban maƙasudin ƙarshen sashi na biyu shine canji a cikin tsananin cutar dermatitis mai raɗaɗi dangane da rahoton kai-da-kai na Indexididdigar Ingantacciyar Rayuwa ta Dermatology (QoL) a cikin kwanaki 14. Maƙasudin ƙarshen na biyu sun haɗa da canji a cikin tsananin cutar dermatitis dangane da tambayoyin Dermatology QoL da kuma abubuwan da suka faru na jiyya-gaggawa mara kyau kamar yadda aka tantance ta Ma'auni na Kalmomi na gama gari don abubuwan da ba su da kyau (CTCAE) ma'auni daga tushe zuwa makonni 12.
"Sakamako mai karfi da aka samu daga marasa lafiya takwas a cikin Sashe na 1 na gwaji na LUT014 don magance RD, ya ba mu ƙarin tabbaci game da yiwuwar wannan maganin kuma ya motsa mu mu fara sashi na 2, a baya fiye da yadda ake tsammani," in ji Benjamin W. Corn. MD, Babban Jami'in Lafiya na Lutris Pharma. “Har ila yau akwai bukatar da ba ta dace ba tsakanin majinyata masu fama da cutar kansar nono da ke fama da RD, wadanda a halin yanzu babu wani zabin jiyya da aka amince da su. LUT014 yana da tsarin ayyuka na musamman wanda ke da nufin daidaita lalata ƙwayoyin sel a cikin basal Layer na fata ta haɓaka haɓakar tantanin halitta, don haka mai yuwuwar juyar da tasirin RD.
"Yin rijistar majiyyaci na ƙarshe a cikin ɓangaren makanta kashi biyu na bincikenmu na 1/2 ya kawo mana mataki ɗaya gaba a cikin ci gaban asibiti na LUT014 a matsayin magani ga RD," in ji Noa Shelach, Ph.D., Babban Jami'in Gudanarwa. Lutris Pharma. "An kiyasta cewa kusan rabin masu ciwon daji ana bi da su tare da maganin radiation, kowace shekara, kuma yawancin masu ciwon nono, musamman, suna fuskantar wani nau'i na RD. Dangane da tsarin aikin LUT014, mun yi imanin cewa LUT104 na iya yin tasiri mai mahimmanci akan wannan yawan masu haƙuri. Muna sa ran bayar da rahoton kwakkwaran bayanai daga wannan gwaji a kashi na uku na wannan shekara."
ABUBUWAN DA ZA KU GUDU DAGA WANNAN LABARI:
- Bazuwar, makafi biyu, kashi biyu mai sarrafa wuribo na kashi na 1/2 na binciken ya shiga jimillar marasa lafiya 20 kuma an tsara shi don kimanta ingancin kulawar LUT014 a cikin marasa lafiya na nono tare da RD.
- "Sakamako mai karfi da aka lura daga marasa lafiya takwas a cikin Sashe na 1 na gwaji na LUT014 don magance RD, ya ba mu ƙarin tabbaci game da yuwuwar wannan maganin kuma ya motsa mu mu fara sashi na 2, a baya fiye da tsammanin,".
- "Yiwa mai haƙuri na ƙarshe a cikin ɓangaren makanta kashi biyu na binciken mu na 1/2 yana kawo mana mataki ɗaya gaba a cikin ci gaban asibiti na LUT014 a matsayin magani ga RD,".
